Ivabradine

Classification place and therapeutic goal

Ivabradine, along with alinidine and falipamil, represents a new pharmacological class — heart rate-lowering agents.

The main therapeutic target when using these drugs is a reliable reduction in myocardial oxygen demand. This effect is achieved exclusively through the development of bradycardia (slowing the heart rate), rather than by lowering blood pressure or depressing cardiac function.

The key advantage of this approach is that the drugs do not exert a negative inotropic effect (myocardial contractility). This property makes ivabradine a particularly valuable tool for treating patients with ischemia combined with concomitant heart failure.

Mechanism of action and hemodynamic effects

The site of action of ivabradine is strictly the sinus node cells. The drug does not affect Purkinje fibers, atrial cardiomyocytes, or atrioventricular node cells.

At the molecular level, the molecule acts as a selective blocker of $I_f$ channels (funny channels). The electrophysiological result of this blockade is the prolongation (lengthening) of the spontaneous diastolic depolarization phase. As a result, the sinus node generates impulses less frequently, and bradycardia develops.

Unlike classic beta-blockers or calcium antagonists, ivabradine acts in a highly isolated and specific manner:

• Conduction: not decreased (the drug does not slow intra-atrial, atrioventricular, or intraventricular conduction).
• Contractility: not depressed (ventricular pumping and contractile function are fully preserved).
• Blood pressure: not lowered (there is no risk of arterial hypotension).

Mechanism of antianginal effect

The reduction in heart rate directly alters the ratio of cardiac cycle phases. Against the background of bradycardia, the duration of diastole — the period of cardiac relaxation — naturally increases.

It is during this prolonged diastole that the most effective blood supply to the myocardium itself occurs. Through this mechanism, two important effects are achieved:

1. The volume of main coronary blood flow increases.
2. Collateral blood flow increases.

As a result, the heart muscle receives more oxygen under conditions of an initially decreased demand for it.

Pharmacokinetic profile

The drug is intended for oral administration (not used sublingually, rectally, or parenterally) and is absorbed in the gastrointestinal tract quite rapidly.

• Bioavailability: is about 40%.
• Distribution: peak plasma concentration ($C_{max}$) is recorded 1.5 hours after administration. Approximately 70% of the active substance binds to plasma proteins.
• Metabolism: occurs in the liver (rather than in blood plasma or kidneys) with the active participation of the cytochrome P-450 3A4 isoenzyme. During biotransformation, an active metabolite is formed — the N-demethylated derivative.
• Elimination: the half-life ($t_{1/2}$) is short, exactly 2 hours (rather than 6 or 24 hours). Metabolite elimination occurs via two pathways: through the kidneys (in urine) and through the intestines (in feces).

Specific side effects

The most typical adverse effect of ivabradine is related to the visual system — phosphenes. Patients may note changes in light perception or sudden flashes of light in their field of vision.

This phenomenon is explained by the fact that $I_f$ channels are present not only in the heart but also in retinal structures of the eye. Blockade of these receptors causes visual anomalies.

It is important to note the high safety profile of the drug in this regard:

• Ivabradine does not lead to morphological (structural) changes in blood vessels or the retina itself.
• Phosphenes are completely reversible. As a rule, they resolve spontaneously within 2 months (rather than weeks or half a year), even if the patient continues therapy.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Comparative characteristics of ivabradine, alinidine, and falipamil
• The role of cytochrome P-450 3A4 in drug-drug interactions
• Electrophysiology of the sinus node and the phase of spontaneous diastolic depolarization
• Features of using heart rate-lowering agents in concomitant heart failure
• Mechanisms of main and collateral myocardial blood flow during diastole

Other topics in the section "Cardiovascular Drugs"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.